This is an MJF funded pre-clinical study by Samsara Therapeutics.
This is a funded pre-clinical study, investigating a similar mechanism of action to MPL.
They hope to get a clinical trial up & running in 2025.
With regards to comments above, going straight to phase 2 would provide a massive advantage over Samsara.
They are running separate pre-clinical trials to try & establish safety & toxicology.
So, they are way behind us in drug development - but it does demonstrate level of interest is high enough to attract funding.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1080
-
- There are more pages in this discussion • 345 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $89.95M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 18.5¢ | $111.6K | 601.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 169572 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 613756 | 10 |
View Market Depth
| Last trade - 15.46pm 30/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |